# A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine

> **NCT00833963** · — · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Breast Cancer
- Pregnancy

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Ado-Trastuzumab Emtansine

## Key facts

- **NCT ID:** NCT00833963
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01-14
- **Primary completion:** 2017-04-13
- **Final completion:** 2017-04-13
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00833963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00833963, "A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00833963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*